256 related articles for article (PubMed ID: 31418132)
1. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332
[TBL] [Abstract][Full Text] [Related]
3. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
[TBL] [Abstract][Full Text] [Related]
4. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
5. Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes.
Yuan ZX; Jia L; Lim LY; Lin JC; Shu G; Zhao L; Ye G; Liang XX; Ji H; Fu HL
Int J Nanomedicine; 2017; 12():5673-5686. PubMed ID: 28848346
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles.
Wang C; Shan Y; Yang J; Xu X; Zhuang B; Fan Y; Xu W
J Biomed Nanotechnol; 2015 May; 11(5):805-15. PubMed ID: 26349393
[TBL] [Abstract][Full Text] [Related]
7. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
8. The use of nanoparticulate delivery systems in metronomic chemotherapy.
Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
[TBL] [Abstract][Full Text] [Related]
9. Modulating tumour vascular normalisation using triptolide-loaded NGR-functionalized liposomes for enhanced cancer radiotherapy.
Xu YY; Chen YH; Jin J; Yuan Y; Li JM; Cai XJ; Zhang RY
J Liposome Res; 2023 Sep; 33(3):251-257. PubMed ID: 36601687
[TBL] [Abstract][Full Text] [Related]
10. Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Lin Y; Peng N; Li J; Zhuang H; Hua ZC
Mol Cancer; 2013 Jun; 12():54. PubMed ID: 23758884
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells.
Zhu W; He S; Li Y; Qiu P; Shu M; Ou Y; Zhou Y; Leng T; Xie J; Zheng X; Xu D; Su X; Yan G
Vascul Pharmacol; 2010; 52(1-2):46-54. PubMed ID: 19854299
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas.
Li X; Mao Y; Li K; Shi T; Yao H; Yao J; Wang S
Drug Deliv; 2016 May; 23(4):1344-54. PubMed ID: 25853479
[TBL] [Abstract][Full Text] [Related]
13. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
14. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
Levitt JM; Jian W; Lerner SP; Sonpavde G
Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
[TBL] [Abstract][Full Text] [Related]
15. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats.
Xue M; Zhao Y; Li XJ; Jiang ZZ; Zhang L; Liu SH; Li XM; Zhang LY; Yang SY
Eur J Pharm Sci; 2012 Nov; 47(4):713-7. PubMed ID: 22677813
[TBL] [Abstract][Full Text] [Related]
16. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
[TBL] [Abstract][Full Text] [Related]
17. Triptolide-targeted delivery methods.
Xu H; Liu B
Eur J Med Chem; 2019 Feb; 164():342-351. PubMed ID: 30605832
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer.
Wang Y; Liu T; Li H
J Biomater Sci Polym Ed; 2016; 27(7):545-56. PubMed ID: 26786618
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.
Shi H; Jiang J; Ji J; Shi M; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Lett; 2014 Jul; 349(2):128-35. PubMed ID: 24746899
[TBL] [Abstract][Full Text] [Related]
20. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats.
Zhang C; Peng F; Liu W; Wan J; Wan C; Xu H; Lam CW; Yang X
Int J Nanomedicine; 2014; 9():1049-63. PubMed ID: 24591827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]